Trimetazidine Reduces Endogenous Free Fatty Acid Oxidation and Improves Myocardial Efficiency in Obese Humans

Cardiovascular Therapeutics

Volumn 30, Issue 6, 2012, Pages 333-341

  Bucci, Marco ^a,b   Borra, Ronald ^a   Någren, Kjell ^a   Pärkkä, Jussi P ^a   Del Ry, Silvia ^b   Maggio, Romina ^a   Tuunanen, Helena ^a   Viljanen, Tapio ^a   Cabiati, Manuela ^c   Rigazio, Sara ^a   Taittonen, Markku ^a   Pagotto, Uberto ^d   Parkkola, Riitta ^a   Opie, Lionel H ^e   Nuutila, Pirjo ^a   Knuuti, Juhani ^a   Iozzo, Patricia ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Fatty acid oxidation; Imaging; Myocardial metabolism; Obesity; Triglyceride turnover; Trimetazidine

Indexed keywords

FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PALMITIC ACID C 11; TRIACYLGLYCEROL; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FATTY ACID OXIDATION; FEMALE; GLUCOSE METABOLISM; HEART MUSCLE; HUMAN; MALE; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; AGED; BODY MASS INDEX; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; HEART FUNCTION TESTS; HEMODYNAMICS; HUMANS; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OBESITY; PALMITATES; POSITRON-EMISSION TOMOGRAPHY; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84869081812     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00275.x     Document Type: Article

References (47)

1. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-588.
2. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003;93:e33-e37.
3. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118:1250-1258.
4. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977.
5. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-313.
6. Mittendorfer B, Peterson LR. Cardiovascular consequences of obesity and targets for treatment. Drug Discov Today Ther Strateg 2008;5:53-61.
7. Kankaanpaa M, Lehto HR, Parkka JP, et al. Myocardial triglyceride content and epicardial fat mass in human obesity: Relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 2006;91:4689-4695.
8. Rijzewijk LJ, Van Der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008;52:1793-1799.
9. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004;109:2191-2196.
10. Mohrman DE, Heller LJ. Cardiovascular physiology. Stamford, CT : Appleton & Lange, 2006.
11. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
12. Nikolaidis MG, Petridou A, Mougios V. Comparison of the phospholipid and triacylglycerol fatty acid profile of rat serum, skeletal muscle and heart. Physiol Res 2006;55:259-265.
13. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: Validation in vivo. Am J Physiol 1999;276:E977-E989.
14. Clarke NE, Mosher RE. The water and electrolyte content of the human heart in congestive heart failure with and without digitalization. Circulation 1952;5:907-914.
15. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994;12:487-495.
16. van der Meer RW, Hammer S, Smit JW, et al. Short-term caloric restriction induces accumulation of myocardial triglycerides and decreases left ventricular diastolic function in healthy subjects. Diabetes 2007;56:2849-2853.
17. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
18. Padgett HC, Robinson GD, Barrio JR. [1-(11)C]palmitic acid: Improved radiopharmaceutical preparation. Int J Appl Radiat Isot 1982;33:1471-1472.
19. 11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia. Nucl Med Biol 2006;33:521-528.
20. Iozzo P, Chareonthaitawee P, Di TM, Betteridge DJ, Ferrannini E, Camici PG. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab 2002;282:E1163-E1171.
21. de Jong HW, Rijzewijk LJ, Lubberink M, et al. Kinetic models for analysing myocardial [(11)C]palmitate data. Eur J Nucl Med Mol Imaging 2009;36:966-978.
22. Bergmann SR, Weinheimer CJ, Markham J, Herrero P. Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med 1996;37:1723-1730.
23. Schon HR, Schelbert HR, Najafi A, Hansen H, Huang H, Barrio J, Phelps ME. C- 11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. II. Kinetics of C- 11 palmitic acid in acutely ischemic myocardium. Am Heart J 1982;103:548-561.
24. 11C-palmitate. J Nucl Cardiol 2009;16:411-421.
25. Bailey JE, Ollis DF. Biochemical engineering fundamentals. New York : McGraw-Hill, 1986.
26. Stipanuk MH. Biochemical, physiological & molecular aspects of human nutrition. Philadelphia, Pa : Elsevier Saunders, 2006.
27. Pilo A, Zucchelli GC, Malvano R, Masini S. Main features of computer algorithms for RIA data reduction; comparison of some different approaches for the interpolation of the dose-response curve. J Nucl Med Allied Sci 1982;26:235-248.
28. Groop LC, Bonadonna RC, Simonson DC, Petrides AS, Shank M, DeFronzo RA. Effect of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity. Am J Physiol 1992;263:E79-E84.
29. Boudina S, Abel ED. Mitochondrial uncoupling: A key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 2006;21:250-258.
30. Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008;52:1006-1012.
31. Taegtmeyer H, Harmancey R. Virchow's metamorphosis revealed triglycerides in the heart. J Am Coll Cardiol 2008;52:1013-1014.
32. Fragasso G, Piatti Md PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003;146:E18.
33. Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997;175:153-162.
34. Sentex E, Helies-Toussaint C, Rousseau D, Lucien A, Ferrary E, Grynberg A. Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs. Fundam Clin Pharmacol 2001;15:255-264.
35. Tabbi-Anneni I, Helies-Toussaint C, Morin D, Bescond-Jacquet A, Lucien A, Grynberg A. Prevention of heart failure in rats by trimetazidine treatment: A consequence of accelerated phospholipid turnover?J Pharmacol Exp Ther 2003;304:1003-1009.
36. Luiken JJ, Niessen HE, Coort SL, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J 2009;419:447-455.
37. Schwarzer M, Faerber G, Rueckauer T, Blum D, Pytel G, Mohr FW, Doenst T. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo. Basic Res Cardiol 2009;104:547-557.
38. Cabrero A, Merlos M, Laguna JC, Carrera MV. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res 2003;44:388-398.
39. Schmitz FJ, Rosen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir. Horm Metab Res 1995;27:515-522.
40. Merrill CL, Ni H, Yoon LW, et al. Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. Toxicol Sci 2002;68:93-101.
41. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, Rhein S. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007;113:205-212.
42. Meier C, Wahllaender A, Hess CW, Preisig R. Perhexiline-induced lipidosis in the dark Agouti (DA) rat. An animal model of genetically determined neurotoxicity. Brain 1986;109(Pt 4):649-660.
43. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001;1:193-204.
44. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135-142.
45. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: Evidence for an indirect mechanism. J Mol Cell Cardiol 1996;28:341-350.
46. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther 2007;321:213-220.
47. Boden WE. Ranolazine and its anti-ischemic effects: Revisiting an old mechanistic paradigm anew?J Am Coll Cardiol 2010;56:943-945.